Objectives: Salmonella enterica strains exhibiting decreased susceptibility to tigecycline have been reported. In this study, we sought to elucidate the roles of Salmonella multidrug efflux pumps and AcrAB regulators in tigecycline resistance.
Introduction
Salmonella causes a variety of diseases in humans, ranging from gastroenteritis to bacteraemia and typhoid fever. 1 In the 1990s, the prevalence of multidrug-resistant Salmonella enterica increased dramatically in the UK, USA and Canada. 2 -5 Many other countries have also documented outbreaks associated with drug-resistant Salmonella in poultry, beef and pork. 6 -10 Emerging resistance in Salmonella has been observed in both humans and animals, and, thus, is a potentially serious public health problem. 11, 12 Drug resistance in bacteria is often associated with multidrug efflux pumps that decrease cellular drug accumulation. 13, 14 Drug resistance in Salmonella spp. is of grave concern, more so in quinolone-resistant and extended-spectrum b-lactamaseproducing isolates that cause complicated infections. This has necessitated the search for newer classes of antimicrobials, such as glycylcyclines. Tigecycline (GAR-936), 9-(t-butylglycylamido)-minocycline, is a novel broad-spectrum antibiotic that is classified as a glycylcycline and is a derivative of minocycline. 15 Modification at the 9 position enables tigecycline to overcome the two major mechanisms responsible for tetracycline resistance: tetracycline-specific efflux pump acquisition; and ribosomal protection. Tigecycline is a poor substrate for tetracycline-specific efflux pumps; it attaches to ribosomes that have been modified by the Tet(M) protein. 15 It has strong antibacterial activity against many Gram-positive and Gram-negative organisms and lacks cross-resistance to other compounds. It is effective against multidrug-resistant pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, extended-spectrum b-lactamase-expressing Enterobacteriaceae and penicillinresistant Streptococcus pneumoniae. However, some bacterial strains are less susceptible to tigecycline. Tigecycline has been reported to have poor activity against Pseudomonas aeruginosa, in which there is active efflux by MexXY -OprM, a member of the resistance -nodulation-cell division (RND) family of efflux pumps. 19 In Enterobacter cloacae, Escherichia coli, Morganella morganii and Klebsiella pneumoniae, it has also been reported that resistance to tigecycline results from overproduction of AcrAB. 20 -23 In E. cloacae and K. pneumoniae, it was reported that tigecycline resistance resulting from overproduction of AcrAB may be caused by overexpression of its positive regulator ramA. 20, 23 S. enterica strains exhibiting decreased susceptibility to tigecycline have recently emerged. 24 A recent study has shown that Salmonella has at least nine multidrug efflux pumps. These pumps are classified into four families: RND; major facilitator; multidrug and toxic compound extrusion; and ATP-binding cassette. 25 Among these pumps, AcrAB is effective in generating multidrug resistance and has wide substrate specificity. AcrAB is induced by multiple regulators, such as MarA, Rob, SoxS, SdiA, RamA and RamR. 26 A recent study suggests that RamA is a master regulator of Salmonella acrAB. 27 RamR is a local repressor of ramA, and RamA and RamR are involved in AcrABmediated multidrug resistance in Salmonella. 28 In this study, we investigated the roles of Salmonella multidrug efflux pumps in resistance to tigecycline and other glycylcyclines using Salmonella multidrug efflux pumps and AcrAB regulatoroverproducing or -deleted strains.
Materials and methods

Bacterial strains, plasmids and growth conditions
Bacterial strains and plasmids used in this study are listed in Table 1 . The strains of S. enterica serovar Typhimurium used in this study are derived from the wild-type strain ATCC 14028s. 29 Bacterial strains were grown at 378C in Luria-Bertani (LB) broth. Ampicillin was added to the growth medium at a final concentration of 100 mg/L for plasmid maintenance.
Construction of gene deletion mutants
To construct the △ramR mutant, gene disruption was performed as described by Datsenko and Wanner. 30 The following oligonucleotide primers were used for the construction of the mutants: ramR-P1 (TCCA ATCCCAGCGCAATATATTCGCCAGCGCGAGCGGGATCGCGCGTGTAGGCTGGAGC TGCTTC); and ramR-P2 (AAGCATTACTGGAAGCGGCAACCCAGGCGATAGCG CAATCCGGTATCATATGAATATCCTCCTTAG). The chloramphenicol resistance gene cat, flanked by Flp recognition sites, was amplified by PCR using the primers listed above. The resulting PCR products were used to transform the recipient ATCC 14028s strain that harbours plasmid pKD46, 
Chemicals
Tigecycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline (DMG-DMDOT), minocycline, doxycycline and tetracycline were obtained from Wyeth-Lederle Japan (Tokyo, Japan).
Determination of MICs of toxic compounds
The MICs of various agents were determined on LB agar plates containing tigecycline, DMG-DMDOT, minocycline, doxycycline and tetracycline at various concentrations. Agar plates were prepared by the 2-fold agar dilution technique as described previously. 31 To determine the MICs, bacteria were grown in LB broth at 378C overnight, diluted into the same medium and then tested at a final inoculum size of 10 5 cfu/mL using a multipoint inoculator (Sakuma Seisakusyo, Tokyo, Japan) after incubation at 378C for 20 h. The MIC was the lowest concentration of the compound that inhibited cell growth.
Results and discussion
Involvement of the tet gene in tigecycline resistance
Previous studies suggest that the tetracycline resistance determinant gene tet does not affect susceptibility to tigecycline in Enterobacteriaceae, S. aureus and S. pneumoniae isolates. 32, 33 In order to confirm whether tet is involved in resistance to MICs of all tested compounds for DacrB harbouring pacrD, pmdtABC, pmdsABC, pemrAB, pmdtK or pmacAB were the same as those for DacrB/vector. MICs of all tested compounds for DtolC harbouring pacrD, pmdtABC, pmdsABC, pemrAB, pmdtK or pmacAB were the same as those for DtolC/vector. MICs of all tested compounds for DacrD, DmdtABC, DmdsABC, DemrAB, DmdfA, DmdtK and DmacAB were the same as those for wild-type. MICs of all tested compounds for DacrAB acrEF acrD, DacrAB acrEF acrD mdtABC, DacrAB acrEF acrD mdtABC mdsABC, DacrAB acrEF acrD mdtABC mdsABC emrAB, DacrAB acrEF acrD mdtABC mdsABC emrAB mdfA and DacrAB acrEF acrD mdtABC mdsABC emrAB mdfA mdtK were the same as those for DacrAB.
MICs of all tested compounds for DmarA, Drob, DsoxS and DsdiA were the same as those for wild-type.
tigecycline in Salmonella, we determined the MICs for strains overexpressing the tet gene. The plasmid pBR322-tet, carrying tetA, which encodes the tetracycline efflux pump TetA, 34, 35 conferred resistance to DMG-DMDOT, which is an early investigational glycylcycline, minocycline, doxycycline and tetracycline in wild-type, DacrB and DtolC strains, but did not confer tigecycline resistance in any strain (Table 2 ). pBR322-Dtet, which does not produce TetA, did not affect susceptibility to the abovementioned compounds (Table 2 ). These results suggest that the tet gene confers resistance to glycylcyclines but is not involved in tigecycline resistance in Salmonella.
Effects of drug efflux pumps on MICs of tigecycline and other glycylcyclines
The plasmids carrying the acrAB, acrEF and mdfA genes conferred resistance to tetracycline in the DacrB mutant (Table 2 ). This is in agreement with the results of a previous study. 25 The plasmids carrying acrAB and acrEF conferred resistance to all tested compounds in the DacrB mutant (2-to 16-fold increase in MICs compared with DacrB/vector) ( Table 2 ). However, the plasmids carrying acrAB and acrEF did not confer resistance to the DtolC mutant. These results indicate that the AcrAB-TolC and AcrEFTolC systems are involved in resistance to tigecycline and other glycylcyclines. Deletion of the acrAB gene resulted in strains with significantly increased (4-to 16-fold compared with wildtype) susceptibility to all tested compounds, although deletion of the acrEF gene did not affect susceptibility to any of the tested compounds (Table 2 ). These results suggest that AcrAB makes a principal contribution to resistance to tigecycline and other glycylcyclines. Stepwise deletion of the nine efflux genes from the DacrAB mutant did not affect susceptibility to any of the tested compounds (Table 2 ). These data support the claim discussed above that AcrAB plays a critical role in resistance to tigecycline and other glycylcyclines.
Involvement of AcrAB regulators in resistance to tigecycline and other glycylcyclines
Deletion of the ramA gene resulted in slightly increased (2-fold decrease in MIC compared with wild-type) susceptibility to tigecycline ( Table 2 ) and overexpression of ramA in the wild-type strain resulted in decreased (2-to 4-fold increase in MICs compared with wild-type) susceptibility to all tested compounds ( Table 2) . Deletion of the ramR gene resulted in significantly decreased (2-to 4-fold increase in MICs compared with wild-type) susceptibility to all tested compounds. Deletion of other AcrAB regulator genes, such as marA, rob, soxS and sdiA, did not affect susceptibility to any of the tested compounds. These results suggest that RamA and RamR are involved in resistance to tigecycline and other glycylcyclines. To investigate the involvement of the AcrB efflux pump in glycylcycline resistance modulated by RamA and RamR, we determined the MICs for the RamA-overproducing DacrB strain and the DacrB ramR double mutant. Neither overproduction of RamA nor RamR deletion in the DacrB mutant affected susceptibility to the tested compounds. These data indicate that RamA and RamR are involved in resistance to tigecycline and other glycylcyclines in an AcrAB-dependent manner.
Conclusions
Our results suggest that AcrAB and its close homologue AcrEF confer tigecycline resistance in S. enterica serovar Typhimurium ATCC 14028s. Results for the DacrAB mutant showed that the AcrAB efflux pump made a significant contribution to resistance to all the compounds that were tested, but that deletion of the acrEF gene did not affect susceptibility to these compounds. These findings may be attributable to the difference in expression level between the acrAB and acrEF genes. A recent study has shown that acrEF is repressed by the histone-like nucleoid structuring protein (H-NS), 36 whereas acrAB is not repressed and is constitutively expressed in S. enterica. 25 AcrAB therefore makes a principal contribution to resistance to tigecycline and other glycylcyclines.
Deletion of the ramA gene, one of several regulators of Salmonella multidrug efflux pumps, resulted in strains with slightly increased susceptibility to tigecycline, and overexpression of the ramA gene resulted in resistance to all tested compounds. Deletion of the ramR gene also resulted in significant resistance to all tested compounds. This resistance, modulated by RamA and RamR, was dependent on the presence of the AcrB efflux pump. Our data suggest that RamA and RamR are effective in exhibiting resistance and that marA, rob, soxS and sdiA do not affect susceptibility to tigecycline and other glycylcyclines.
In this study, we elucidated the mechanism of tigecycline resistance in Salmonella. Our results suggest that the AcrABTolC and AcrEF-TolC systems play a role in resistance to tigecycline and other glycylcyclines, and that AcrAB makes a major contribution. In addition, overexpression of ramA and inactivation of ramR conferred increased (4-fold) resistance to tigecycline in an AcrAB-dependent manner.
